HER2-low breast cancers: Current insights and future directions

Huina Zhang, Cansu Karakas, Haley Tyburski, Bradley M. Turner, Yan Peng, Xi Wang, Hani Katerji, Linda Schiffhauer, David G. Hicks

Research output: Contribution to journalReview articlepeer-review

Abstract

In light of the significant clinical benefits of novel HER2-targeting antibody-drug conjugates in advanced HER2-low expressing breast cancers in recent phases I and III clinical trials, particularly trastuzumab-deruxtecan (T-Dxd), the new “HER2-low” category in breast cancers (breast cancer with a HER2 IHC score of 1+, or 2+ without gene amplification) has gained increasing attention. In the past year, “HER2-low” breast cancers have been under active investigation by both oncologists and pathologists. In this current review, we update the recent cutting-edge research on HER2-low breast cancers, with a focus on the biology of HER2-low breast cancers, the issues on the identification of HER2-low breast cancers by immunohistochemistry in current practice of pathology, and the future directions in this emerging category in breast cancers.

Original languageEnglish (US)
Pages (from-to)305-312
Number of pages8
JournalSeminars in Diagnostic Pathology
Volume39
Issue number5
DOIs
StatePublished - Sep 2022

Keywords

  • Biology
  • Breast cancer
  • HER2
  • HER2-low
  • Pathology
  • T-Dxd
  • Trastuzumab-deruxtecan

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Fingerprint

Dive into the research topics of 'HER2-low breast cancers: Current insights and future directions'. Together they form a unique fingerprint.

Cite this